Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review

被引:10
|
作者
Letarouilly, Jean-Guillaume [1 ]
Salmon, Jean-Hugues [2 ]
Flipo, Rene-Marc [1 ]
机构
[1] CHU Lille, Rheumatol, F-59000 Lille, France
[2] Univ Reims, Dept Rheumatol, Reims, France
关键词
Biologic treatments; drug survival; maintenance; persistence; rheumatoid arthritis; MODIFYING ANTIRHEUMATIC DRUGS; CLINICAL-PRACTICE; EXTERNAL VALIDITY; ELDERLY-PATIENTS; ALPHA INHIBITOR; TNF INHIBITORS; DMARD THERAPY; SURVIVAL; INFLIXIMAB; ADHERENCE;
D O I
10.1080/14740338.2021.1924146
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Biologic treatments are a milestone in the management of rheumatoid arthritis (RA) patients with an inadequate response to conventional synthetic treatments. With the increase in the number of biologic treatments, predictor factors of discontinuation are needed to choose the right treatment for the right patient. Areas covered: In this article, the factors affecting persistence with biologic treatments will be covered: factors associated with the demographic characteristics and comordidities of the patients, those with the characteristics of the disease, the biomarkers, and the adherence. Expert opinion: Seeking factors affecting persistence with biologic treatments is an important field of clinical research to offer the best management to the RA patients. Personalized medicine is the ultimate goal in this field to choose the biological therapy with the highest persistence for every patient. To achieve this goal, biomarkers could be a milestone.
引用
收藏
页码:1087 / 1094
页数:8
相关论文
共 50 条
  • [21] Nursing sensitive outcomes in patients with rheumatoid arthritis: A systematic literature review
    Minnock, Patricia
    McKee, Gabrielle
    Kelly, Alexia
    Carter, Sheree C.
    Menzies, Victoria
    O'Sullivan, Denis
    Richards, Pam
    Ndosi, Mwidimi
    Hustings, Yvonne van Eijk
    INTERNATIONAL JOURNAL OF NURSING STUDIES, 2018, 77 : 115 - 129
  • [22] Infectious complications of biologic treatments of rheumatoid arthritis
    Mohan, AK
    Coté, TR
    Siegel, JN
    Braun, MM
    CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (03) : 179 - 184
  • [23] Patient Preferences for Biologic Treatments in Rheumatoid Arthritis
    Nafees, Beenish
    Lloyd, Andrew
    Gaich, Carol L.
    Birt, Julie
    Hughes, Rodney A.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S213 - S213
  • [24] Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review
    Roubille, Camille
    Haraoui, Boulos
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 43 (05) : 613 - 626
  • [25] COMPARISON OF ABATACEPT AND OTHER BIOLOGIC DMARDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
    Hochberg, M.
    Janssen, K.
    Broglio, K.
    Walsem, A. V.
    Nadkarni, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 676 - 676
  • [26] COST-EFFECTIVENESS OF PHARMACOLOGICAL RHEUMATOID ARTHRITIS TREATMENTS IN THE UNITED STATES: A SYSTEMATIC REVIEW OF THE LITERATURE
    Axon, D. R.
    Patel, M.
    VALUE IN HEALTH, 2017, 20 (05) : A145 - A145
  • [27] PATIENTS' PREFERENCES FOR RHEUMATOID ARTHRITIS TREATMENTS AND THEIR PARTICIPATION IN THE TREATMENT DECISION-MAKING PROCESS. A SYSTEMATIC REVIEW OF THE LITERATURE
    Dilla, T.
    Rentero, M. L.
    Comellas, M.
    Lizan, L.
    Sacristan, J. A.
    VALUE IN HEALTH, 2015, 18 (07) : A652 - A652
  • [28] Risk factors for hypertension in rheumatoid arthritis patients-A systematic review
    Hadwen, Brook
    Stranges, Saverio
    Barra, Lillian
    AUTOIMMUNITY REVIEWS, 2021, 20 (04)
  • [29] Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature
    Chen, Der-Yuan
    Lau, Chak Sing
    Elzorkany, Bassel
    Hsu, Ping-Ning
    Praprotnik, Sonja
    Vasilescu, Radu
    Marshall, Lisa
    Llamado, Lyndon
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (02) : 362 - 372
  • [30] Cost of Biologic Treatment Persistence or Switching in Rheumatoid Arthritis
    Gu, Tao
    Mutebi, Alex
    Stolshek, Bradley S.
    Tan, Hiangkiat
    AMERICAN JOURNAL OF MANAGED CARE, 2018, 24 (08): : SP338 - SP345